Search

LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally

Extends ProQR’s cash runway into 2023ProQR can trigger conversion of the debt to equity at $7.88 per share, under certain conditions LEIDEN, Netherlands & CAMBRIDGE, Mass. , July 14, 2020 (GLOBE NEWSWIRE) --

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that it intends to offer

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Company’s

Senior leader with extensive global rare disease commercialization experience Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.